- Home
- HNRG vs DAWN Comparison
HNRG vs DAWN Comparison
Compare HNRG & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HNRG | DAWN |
|---|---|---|
| Founded | 1949 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 833.6M | 908.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | HNRG | DAWN |
|---|---|---|
| Price | $19.93 | $12.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $21.00 | ★ $27.56 |
| AVG Volume (30 Days) | 600.5K | ★ 2.5M |
| Earning Date | 11-10-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $461,142,000.00 | $133,672,000.00 |
| Revenue This Year | $18.77 | $17.32 |
| Revenue Next Year | N/A | $53.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 7.15 | ★ 31.11 |
| 52 Week Low | $8.37 | $5.64 |
| 52 Week High | $24.70 | $13.53 |
Technical Indicators
Market Signals| Indicator | HNRG | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 51.88 | 67.13 |
| Support Level | $18.39 | $10.16 |
| Resistance Level | $20.73 | $11.18 |
| Average True Range (ATR) | 1.05 | 0.81 |
| MACD | 0.12 | 0.20 |
| Stochastic Oscillator | 66.86 | 99.60 |
Price Performance
Historical ComparisonAbout HNRG Hallador Energy Company
Hallador Energy Co is a coal mining company with operations in Indiana, USA, and it is part of the electric power generation industry. The operations of the company are divided into two primary reportable segments, the Coal Operations and Electric Operations segments. The majority of revenue is earned from the Coal Operations segment.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.